
Ascendis Pharma Investor Relations Material
Latest events

Q1 2025
Ascendis Pharma
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Ascendis Pharma A/S
Access all reports
Ascendis Pharma A/S is a biopharmaceutical company leveraging its TransCon technology platform to develop treatments for patients with unmet medical needs in endocrinology and oncology. The company's proprietary TransCon technology is designed to enhance the efficacy, safety, and administration of existing molecules, resulting in new therapies that could potentially offer best-in-class benefits. Ascendis Pharma's approach combines the benefits of prodrug and sustained-release technologies, enabling the controlled release of active pharmaceutical ingredients. The company is headquartered in Copenhagen, Denmark, and its shares are listed on the NASDAQ under the ticker symbol ASND.
Key slides for Ascendis Pharma A/S


Investor Update
Ascendis Pharma A/S


43rd Annual J.P. Morgan Healthcare Conference 2025
Ascendis Pharma A/S
Latest articles
)
Figma: Collaborative Design Tool Ready for IPO
Figma, the popular design platform, is preparing for a potential IPO in 2025 as it continues to reshape the future of collaborative design.
22 May 2025
)
Companies That Had Their IPO in 2024: Momentum Increasing
2024 marked a steady year for IPOs, driven by strong markets, AI momentum, and high-profile listings across industries and regions.
22 May 2025
)
The Rise and Fall of Wirecard
A look inside the Wirecard scandal, which took the company from the prestigious DAX 30 to insolvency through the largest accounting fraud in European history.
16 May 2025
Ticker symbol
ASND
Country
🇺🇸 United States